Loretta J. Nastoupil, MD

Over the past 10 years, more barriers have become apparent in the process of getting insurance companies to approve cancer treatments, according to Loretta Nastoupil, MD.

Although institutional cancer centers boast large amounts of resources, community centers do not always have the resources to initiate clinical trials, according to Loretta Nastoupil, MD.

The consolidation of oncologists and the transition to bispecific antibodies and CAR T-cell therapies are among factors that have led to increasing cancer care costs.

Balancing the goal of obtaining a durable remission and that of avoiding a negative impact on quality of life argues against the routine use of chemotherapy in follicular lymphoma.

The rationale for maintenance therapy in indolent non-Hodgkin lymphoma was derived from historical data suggesting that despite robust response rates to standard therapy, most patients eventually relapse and disease-free intervals become progressively shorter.

This review will cover innovative therapeutic approaches in relapsed or refractory MCL, many of which have the potential to alter treatment paradigms toward the development of strategies that do not involve conventional chemotherapy agents.

This article examines clinical and biological features of DLBCL patients with poor outcomes, and reviews recent studies addressing alternatives to standard front-line management strategies together with unresolved questions.